EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Basculer en Français

10964	Companies
239965	Keywords
168732	Articles
129105	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

PRESS RELEASE

published on 04/16/2024 at 15:00, 2 years 4 months ago

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation

VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRIEF

published on 04/09/2024 at 14:50, 2 years 5 months ago

EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
BRIEF

published on 04/09/2024 at 14:50, 2 years 5 months ago

EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve®

EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
PRESS RELEASE

published on 04/09/2024 at 14:45, 2 years 5 months ago

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024

FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
BRIEF

published on 03/15/2024 at 14:05, 2 years 5 months ago

EnVVeno Medical to Showcase Its Innovations in an Upcoming Virtual Investor Event

EnVVeno Medical Medical Innovation Virtual Investor Event Venous Disease Treatment Corporate Overview
BRIEF

published on 03/15/2024 at 14:05, 2 years 5 months ago

EnVVeno Medical présentera ses innovations lors d'un prochain événement virtuel pour les investisseurs

Innovation Médicale EnVVeno Medical Événement Virtuel Pour Les Investisseurs Traitement Des Maladies Veineuses Vue D'ensemble De L'entreprise
PRESS RELEASE

published on 03/15/2024 at 14:00, 2 years 5 months ago

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
enVVeno Medical to present at Virtual Investor Lunch Break on March 21, 2024, with CEO Robert Berman discussing the company's outlook and the enVVeno Opportunity

EnVVeno Medical Venous Disease Treatment Virtual Investor Lunch Break Robert Berman Bioprosthetic Solutions
BRIEF

published on 03/06/2024 at 14:45, 2 years 6 months ago

EnVVeno Medical Corporation Announces Positive Results from VenoValve Pivotal Trial

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Clinical Improvement
BRIEF

published on 03/06/2024 at 14:45, 2 years 6 months ago

EnVVeno Medical Corporation annonce les résultats positifs de l'essai pivot VenoValve

EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Approbation De La FDA Amélioration Clinique
PRESS RELEASE

published on 03/06/2024 at 14:40, 2 years 6 months ago

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
enVVeno Medical presents positive topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum Annual Meeting, showing significant clinical improvement in CVI patients

EnVVeno Medical VenoValve Clinical Improvement SAVVE Trial CVI Patients

Accesswire

Published on 09/10/2026 at 22:25, 2 hours 10 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 6 hours 49 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 9 hours 15 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 9 hours 35 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 9 hours 58 minutes ago

Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 00:05, 30 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 34 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 1 hour 55 minutes ago

EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 2 hours 24 minutes ago

flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 2 hours 28 minutes ago

EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board

Les Echos

Published on 09/10/2026 at 19:30, 5 hours 5 minutes ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 5 hours 5 minutes ago

Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 6 hours 25 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 6 hours 50 minutes ago

COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 6 hours 52 minutes ago

Déclaration d'actions et de droits de vote au 31.08.2026

View all LES ECHOS COMFI WIRE